sd-1077

SD-1077 is a deuterium containing levodopa. SD-1077 has been shown in preclinical models to improve the half-life of dopamine in the brain resulting in a prolonged treatment effect.

L-DOPA-2,5,6-D3 is a deuterated isotope of L-Dopa for isotope tracing. L-DOPA (T0848) is an orally active metabolic precursor of the neurotransmitter dopamine, capable of crossing the blood-brain barrier and converting to dopamine within the brain. It exhibits anti-hyperalgesic effects and is utilised in Parkinson's disease research.

L-DOPA-D6 is the deuterium-labeled analog of L-DOPA. L-DOPA (T0848) (Levodopa) serves as an orally active metabolic precursor to the neurotransmitter dopamine. It is capable of crossing the blood-brain barrier and is subsequently converted into dopamine within the brain. L-DOPA (T0848) exhibits anti-hyperalgesic properties and holds potential for Parkinson's disease research.

L-DOPA belongs to the category of dopamine precursors, serving as an orally active neurotransmitter metabolic precursor capable of crossing the blood-brain barrier and undergoing conversion to dopamine within the brain. The compound exhibits anti-hyperalgesic properties and finds application in Parkinson's disease research as well as in the induction of disease models.

L-DOPA-13C6 is L-DOPA (T0848) labeled with 13C. L-DOPA (Levodopa) serves as an orally active metabolic precursor to the neurotransmitter dopamine. It can cross the blood-brain barrier and is converted to dopamine in the brain. L-DOPA (T0848) exhibits anti-nociceptive effects and shows potential in Parkinson's disease research.

L-DOPA-13C is the 13C labeled version of L-DOPA. L-DOPA (T0848) (Levodopa) is an orally active metabolic precursor of the neurotransmitter dopamine. It can cross the blood-brain barrier and is transformed into dopamine within the brain. L-DOPA (T0848) exhibits anti-nociceptive properties and holds potential for Parkinson's disease research.